YPSOMED HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 411 CHF | +0.61% |
|
+4.45% | +35.64% |
| Jun. 20 | Ypsomed Partner Secures US FDA Nod for Automated Insulin Delivery Algorithm | MT |
| Jun. 12 | German Pharmaceutical Medac Picks Ypsomed Autoinjector for Methotrexate Pen Relaunch | MT |
Evolution of the average Target Price on Ypsomed Holding AG
Price target over the last 5 years
History of analyst recommendation changes
6f33786dcdba3429a6f.UnD2eH6kZaB5dpSnHfGIchnffeWnizmKf1V64ASFSO0.ZUDGTBP2LdU2McvgRa7jJn2XTN3kzXq5Lgw4kTXmH4ljEYRKTssUygsCwQ~52272c1fe54c1d5533ce1924c8a8f734
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
411
CHF
Average target price
378
CHF
Spread / Average Target
-8.03%
High Price Target
430
CHF
Spread / Highest target
+4.62%
Low Price Target
326
CHF
Spread / Lowest Target
-20.68%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Ypsomed Holding AG
| Octagon Capital | |
| Credit Suisse | |
| Banco Santander | |
| Research Capital | |
| Bank of America Securities/Merrill Lynch |
Trading Rating
Investor Rating
ESG Refinitiv
B-
EPS Revisions
- Stock Market
- Equities
- YPSN Stock
- Consensus Ypsomed Holding AG
